Alps Advisors Inc Bei Gene, Ltd. Transaction History

Alps Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 25, 2018	SELL	$152.5 - $216.77 $807,640 - $1.15 Million	-5,296 Reduced 9.51%	50,382 $4.92 Million
Q1 2018 May 01, 2018	BUY	$97.41 - $177.22 $515,883 - $938,557	5,296 Added 10.51%	55,678 $9.35 Million
Q4 2017 Feb 05, 2018	BUY	$79.6 - $114.73 $687,982 - $991,611	8,643 Added 20.71%	50,382 $4.92 Million
Q3 2017 Nov 03, 2017	BUY	$66.19 - $103.46 $2.76 Million - $4.32 Million	41,739	41,739 $4.32 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.